Philippe Merle
Impact in
- Hepatology top 0.05%
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis C virus research
- Liver physiology and pathology
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
Papers in
- Hepatology 125
- Hepatocellular Carcinoma Treatment and Prognosis 109
- Hepatitis C virus research 14
- Oncology 74
- Colorectal Cancer Treatments and Studies 34
- Pancreatic and Hepatic Oncology Research 19
- Cancer Immunotherapy and Biomarkers 14
- Co-authors
- Masatoshi Kudo (49 shared papers)Ann‐Lii Cheng (42 shared papers)Richard S. Finn (37 shared papers)В. В. Бредер (25 shared papers)Andrew X. Zhu (23 shared papers)Ho Yeong Lim (24 shared papers)Jack R. Wands (7 shared papers)Julien Edeline (24 shared papers)
- Journals
- Journal of Clinical Oncology (46 papers)Annals of Oncology (27 papers)Journal of Hepatology (17 papers)Liver Cancer (10 papers)British Journal of Cancer (4 papers)
- Partner nations
- FranceUnited StatesTaiwan
In The Last Decade
Philippe Merle
203 papers receiving 9.2k citations
Philippe Merle's Hit Papers
Peers
Comparison fields: 5 of 119
- Hepatology 4.6k
- Oncology 2.4k
- Cancer Research 1.2k
- Pathology and Forensic Medicine 1.1k
- Epidemiology 1.8k
Countries citing papers authored by Philippe Merle
This map shows the geographic impact of Philippe Merle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Merle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Merle more than expected).
Fields of papers citing papers by Philippe Merle
This network shows the impact of papers produced by Philippe Merle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Merle. The network helps show where Philippe Merle may publish in the future.
Co-authors
The 25 scholars most cited alongside Philippe Merle, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 211 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial Hit paper breakdown → | 2019 | 1329 |
| 2 | Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma Hit paper breakdown → | 2021 | 964 |
| 3 | CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) Hit paper breakdown → | 2019 | 499 |
| 4 | 2002 | 278 | |
| 5 | 2018 | 251 | |
| 6 | IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). Hit paper breakdown → | 2021 | 233 |
| 7 | 2013 | 224 | |
| 8 | 2019 | 203 | |
| 9 | 2004 | 203 | |
| 10 | 2000 | 177 | |
| 11 | 2008 | 175 | |
| 12 | 2019 | 172 | |
| 13 | 2005 | 168 | |
| 14 | 2006 | 160 | |
| 15 | 2019 | 159 | |
| 16 | 2008 | 153 | |
| 17 | 2019 | 152 | |
| 18 | 2001 | 141 | |
| 19 | 2000 | 139 | |
| 20 | LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC) Hit paper breakdown → | 2022 | 138 |
About Philippe Merle
Philippe Merle is a scholar working on Hepatology, Oncology, Pulmonary and Respiratory Medicine, Epidemiology and Molecular Biology, having authored 211 papers that have together received 9.3k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (109 papers), Colorectal Cancer Treatments and Studies (34 papers), Hepatitis B Virus Studies (24 papers), Pancreatic and Hepatic Oncology Research (19 papers), Liver Disease Diagnosis and Treatment (17 papers), Lung Cancer Treatments and Mutations (16 papers), Hepatitis C virus research (14 papers) and Cancer Immunotherapy and Biomarkers (14 papers). The work is most often cited by research in Hepatology (4.6k citations), Oncology (2.4k citations), Cancer Research (1.2k citations), Pathology and Forensic Medicine (1.1k citations) and Epidemiology (1.8k citations). Philippe Merle has collaborated with scholars based in France, United States and Taiwan. Frequent co-authors include Masatoshi Kudo, Ann‐Lii Cheng, Richard S. Finn, В. В. Бредер, Andrew X. Zhu, Ho Yeong Lim, Jack R. Wands, Julien Edeline, Thomas Yau and Christian Trépo. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Hepatology, Liver Cancer and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.